Genetic Determinants of the Bronchodilatation Effect of Albuterol ex-Vivo
Information source: Hadassah Medical Organization
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Intervention: albuterol (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Hadassah Medical Organization Official(s) and/or principal investigator(s):
Yoseph Caraco, ND, Principal Investigator, Affiliation: Hadassah Medical Organization
Overall contact:
Arik Tzukert, DMD, Phone: 00 972 2 6776095, Email: arik@hadassah.org.il
Summary
The role played by ß2AR polymorphisms in determining the bronchial response to ß2AR agonist
drugs, has been confirmed by several studies.
The purpose of the present study is to examine possible causal relationships between
genetically based alteration in the structure of ß2AR and drug responsiveness. An ex-vivo
model (organ bath technique) will be used to investigate association between polymorphisms
in the coding region of ß2AR and the response of bronchial rings derived from human lung
tissue to the respective agonists (i. e. salbutamol).
In the second part of the study the same bronchial rings will be incubated for 24 hours in a
solution containing fixed concentration of albuterol. A second dose response curve for
rising concentrations of albuterol will be constructed and a relationship between β2 genetic
polymorphisms and the extent of desensitization to albuterol will be investigated.
In addition, through specifically designed receptor binding assay the bronchial tissue will
be used to define the affinity (Kd) and expression (Vmax) of the ß2 receptor. These data
will enable to enhance our understanding regarding the mechanism responsible for the
association noted between ß2AR polymorphism and altered drug effect.
Clinical Details
Official title: The Effect of β2 Genetic Polymorphisms on the Brochodilatation Effect of Albuterol ex-Vivo
Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacodynamics Study
Primary outcome: The extent of bronchial dilatation ex-vivoThe extent of decrease in brochial dilatation after prolonged incubation with albuterol
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Macroscopically normal pulmonary tissue
Exclusion Criteria:
- The presence of pathological finding in the pulmonary tissue
Locations and Contacts
Arik Tzukert, DMD, Phone: 00 972 2 6776095, Email: arik@hadassah.org.il
Hadassah Medical Organization, Jerusalem, Israel; Recruiting
Arik Tzukert, DMD, Phone: 00 972 2 6776095, Email: arik@hadassah.org.il
Hadas Lemberg, PhD, Phone: 00 972 2 6777572, Email: lhadas@hadassah.org.il
Yoseph Caraco, MD, Principal Investigator
Additional Information
Starting date: August 2003
Last updated: October 28, 2008
|
